Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Akanda Corp (AKAN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: AKAN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -59.13% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.30M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.5 | 52 Weeks Range 0.93 - 5.08 | Updated Date 06/29/2025 |
52 Weeks Range 0.93 - 5.08 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.14 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -564.33% |
Management Effectiveness
Return on Assets (TTM) -32.7% | Return on Equity (TTM) -1460.27% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -185776 | Price to Sales(TTM) 3.94 |
Enterprise Value -185776 | Price to Sales(TTM) 3.94 | ||
Enterprise Value to Revenue 3.2 | Enterprise Value to EBITDA -0.8 | Shares Outstanding 2275900 | Shares Floating 2257628 |
Shares Outstanding 2275900 | Shares Floating 2257628 | ||
Percent Insiders 0.8 | Percent Institutions 0.51 |
Upturn AI SWOT
Akanda Corp
Company Overview
History and Background
Akanda Corp was a medical cannabis company focused on international markets. It aimed to cultivate and distribute medical cannabis products. The company's operations were primarily based in Lesotho, Africa, and Portugal. Due to struggles with revenue and market access Akanda Corp ceased operations in 2023.
Core Business Areas
- Cultivation: Akanda Corp cultivated medical cannabis in Lesotho and Portugal, aiming to produce high-quality cannabis flower and extracts.
- Distribution: The company focused on distributing its products to medical cannabis markets in Europe and other regions.
- Pharmaceutical: Akanda Corp had plans to develop pharmaceutical-grade cannabis products.
Leadership and Structure
Akanda Corp's leadership team consisted of executives with experience in the cannabis industry and international business. The organizational structure was designed to support its cultivation, distribution, and pharmaceutical operations. Tejinder Virk was the CEO.
Top Products and Market Share
Key Offerings
- Medical Cannabis Flower: Akanda Corp produced medical cannabis flower for distribution to pharmacies and other medical outlets. Market share data is not available due to the company's relatively small size and limited market presence. Competitors include larger cannabis producers such as Canopy Growth and Aurora Cannabis.
- Cannabis Extracts: Akanda Corp also produced cannabis extracts, including oils and concentrates, for use in medical cannabis products. Market share data is limited. Competitors include Aphria (now Tilray) and Cronos Group.
Market Dynamics
Industry Overview
The medical cannabis industry is characterized by increasing legalization and acceptance, growing patient demand, and evolving regulatory frameworks. The industry faces challenges such as competition, regulatory uncertainty, and the need for product standardization.
Positioning
Akanda Corp aimed to position itself as a supplier of high-quality medical cannabis products to international markets. Its competitive advantages were intended to include its low-cost cultivation operations in Lesotho and its focus on pharmaceutical-grade products.
Total Addressable Market (TAM)
The global medical cannabis market is projected to reach hundreds of billions of dollars in the coming years. Akanda Corp was positioned to capture a small share of this market through its cultivation and distribution operations. Due to not becoming successful the total market share was never reached.
Upturn SWOT Analysis
Strengths
- Low-cost cultivation operations in Lesotho
- Focus on pharmaceutical-grade products
- Access to international markets
Weaknesses
- Limited financial resources
- Relatively small market presence
- Operational challenges in Lesotho
- Uncertainty of revenues and business model
Opportunities
- Expansion into new international markets
- Development of innovative cannabis products
- Partnerships with pharmaceutical companies
- Increase in market share.
Threats
- Competition from larger cannabis producers
- Regulatory uncertainty
- Fluctuations in cannabis prices
- Operational risks in Lesotho
Competitors and Market Share
Key Competitors
- TLRY
- CGC
- ACB
- CRON
Competitive Landscape
Akanda Corp faced significant disadvantages compared to its larger competitors due to its limited financial resources and market presence.
Growth Trajectory and Initiatives
Historical Growth: Akanda Corp's growth was limited due to operational challenges and market access issues.
Future Projections: There are no future projections due to the company ceasing its operations.
Recent Initiatives: Recent initiatives included efforts to expand into new markets and develop new products. However, none of those became successful.
Summary
Akanda Corp was a medical cannabis company with a focus on international markets. It had some strengths, such as low-cost cultivation operations, but it also faced significant challenges, including limited financial resources and competition from larger producers. The company's financial performance was weak, and its growth trajectory was limited and it eventually ceased operation in 2023.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Industry reports
- Market analysis
Disclaimers:
The data and analysis provided are based on available information and are subject to change. This is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Akanda Corp
Exchange NASDAQ | Headquaters Toronto, ON, Canada | ||
IPO Launch date 2022-03-15 | Interim CEO & Executive Director Ms. Katharyn Field | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees - | Website https://www.akandacorp.com |
Full time employees - | Website https://www.akandacorp.com | ||
Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis-based products. The company was incorporated in 2021 and is headquartered in Toronto, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.